Natural Capsules Limited (524654) Earnings Call Transcripts

Natural Capsules Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Natural Capsules Limited reported a consolidated revenue of INR 58.45 crores, reflecting a strong 55% growth quarter-on-quarter and 30% year-on-year. However, the company posted a net loss of INR 4.98 crores, primarily due to high depreciation and finance costs. For FY '26, total revenue reached INR 187.20 crores, an 11% increase from the previous year, but EBITDA was a loss of INR 1.56 crores, significantly down from a profit of INR 17.52 crores in FY '25. Management maintained a cautious outlook, signaling a focus on restoring profitability in FY '27 while targeting revenue growth from new product lines and improved operational efficiency.

Reported metrics

Guidance from management

Management has set a conservative revenue guidance for FY '27, targeting INR 274 crores in total revenue, with specific contributions of INR 170 crores from gelatin capsules, INR 20 crores from HPMC capsules, and INR 70 crores from API sales.

What management said

So there are various options. We have also made an application under government's RDA scheme to Burak, and I am hopeful that we might get some funding as being a deep tech company here in pharma API line. We expect to contribute equal amount from our side, which should be in form of equity. We might do a kind of a preferential allotment where the promoters could also participate and we could also do a right issue. So...

No, the clawback clause is referring to FY '29 figures. And that also is -- this is already mentioned in our shareholders' agreement, and this is for FY '29. So as far as it is concerned, at this point in time, there's no discussion on that.

What analysts pressed on

Analysts expressed concerns over the company's ability to manage multiple strategic initiatives simultaneously, particularly given the current liquidity pressures and ongoing operational challenges. There were also questions regarding the timeline for regulatory approvals and the potential impact of delayed HPMC revenue on overall profitability.

Main topics on the call

• Revenue Growth — Natural Capsules reported Q4 FY '26 revenue of INR 58.45 crores, a 55% increase quarter-on-quarter and a 30% increase year-on-year. Management noted that 'approximately INR 6 crores of revenue in the quarter reflect thos...
• Profitability Challenges — Despite revenue growth, the company faced significant profitability challenges with an EBITDA loss of INR 1.56 crores for FY '26, down from a profit of INR 17.52 crores in FY '25. Management acknowledged that 'the operat...
• API Commercial Sales — Management announced the commencement of commercial API sales at the Tumkur facility, marking a significant milestone. They expect this segment to contribute approximately INR 70 crores in FY '27, though margins are anti...
• HPMC Line Expectations — The new HPMC line is expected to generate INR 20 crores in revenue for FY '27, contingent on U.S. customer approvals. Management stated, 'We are actively progressing those approvals,' indicating a strategic focus on regu...

Read the full Natural Capsules Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 4 Natural Capsules Limited earnings call transcripts on record, spanning November 18, 2024 to June 2, 2026. Based on this history, Natural Capsules Limited reports semi-annually. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

524654

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

4

First call

November 18, 2024

Most recent

June 2, 2026

Reporting cadence

semi-annually